Pfizer, Inc. (PFE) Short Interest Down 11.9% in October

Pfizer, Inc. (NYSE:PFE) was the target of a significant decline in short interest in October. As of October 31st, there was short interest totalling 51,408,403 shares, a decline of 11.9% from the October 13th total of 58,325,639 shares. Currently, 0.9% of the company’s shares are short sold. Based on an average daily volume of 17,276,742 shares, the days-to-cover ratio is currently 3.0 days.

Several equities research analysts have recently commented on PFE shares. UBS AG restated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a report on Monday, July 31st. Berenberg Bank set a $39.00 price objective on Pfizer and gave the company a “neutral” rating in a report on Tuesday, August 1st. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $33.00 to $37.00 in a report on Wednesday, August 2nd. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Finally, BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $38.48.

Pfizer (PFE) opened at $35.37 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a 1 year low of $30.51 and a 1 year high of $36.78. The firm has a market capitalization of $211,960.00, a price-to-earnings ratio of 14.15, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the previous year, the firm earned $0.61 earnings per share. The business’s revenue was up .9% on a year-over-year basis. equities analysts expect that Pfizer will post 2.6 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.62%. Pfizer’s dividend payout ratio is currently 78.53%.

In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Over the last quarter, insiders sold 374,621 shares of company stock valued at $12,796,098. 0.06% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Altfest L J & Co. Inc. boosted its position in Pfizer by 67.0% in the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after purchasing an additional 43,024 shares during the last quarter. HL Financial Services LLC lifted its position in shares of Pfizer by 1.1% during the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after buying an additional 35,744 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Pfizer during the 1st quarter valued at $13,342,000. Searle & CO. lifted its position in shares of Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after buying an additional 38,500 shares during the last quarter. Finally, Hartford Financial Management Inc. lifted its position in shares of Pfizer by 10.8% during the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 835 shares during the last quarter. 69.36% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Pfizer, Inc. (PFE) Short Interest Down 11.9% in October” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/18/pfizer-inc-pfe-short-interest-down-11-9-in-october.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit